Dantrolene

Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Dantrolene and local guidelines before prescribing.

Muscle relaxant (ryanodine blocker)

Mechanism

Inhibits ryanodine receptor calcium release from sarcoplasmic reticulum.

Uses

Malignant hyperthermia, neuroleptic malignant syndrome (selected), spasticity.

Dosing

Side effects

Muscle weakness, drowsiness, hepatotoxicity, phlebitis.

Interactions

Calcium channel blockers (IV) risk hyperkalaemia and cardiovascular collapse.

Contraindications and cautions

Liver disease (chronic oral); respiratory muscle weakness

Monitoring

LFT, muscle strength

Pregnancy and breastfeeding

Used in emergencies

Renal and hepatic impairment

Caution in hepatic impairment

Overdose and reversal

Supportive

Special advice

Early IV use in malignant hyperthermia with supportive cooling; monitor LFT with prolonged use.

More from the textbook: uses, cautions and other points
Where it is discussed in the book